|
1
|
Jiang S, Wang G, Chen J and Dong Y:
Comparison of clinical features and outcomes in patients with
extraskeletal vs skeletal Ewing sarcoma: An SEER database analysis
of 3,178 cases. Cancer Manag Res. 10:6227–6236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grier HE, Krailo MD, Tarbell NJ, Link MP,
Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers
PA, et al: Addition of ifosfamide and etoposide to standard
chemotherapy for Ewing's sarcoma and primitive neuroectodermal
tumor of bone. N Engl J Med. 348:694–701. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferrari S, Mercuri M, Rosito P, Mancini A,
Barbieri E, Longhi A, Rimondini S, Cesari M, Ruggieri P, Di Liddo M
and Bacci G: Ifosfamide and actinomycin-D, added in the induction
phase to vincristine, cyclophosphamide and doxorubicin, improve
histologic response and prognosis in patients with non metastatic
Ewing's sarcoma of the extremity. J Chemother. 10:484–491. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Juergens C, Weston C, Lewis I, Whelan J,
Paulussen M, Oberlin O, Michon J, Zoubek A, Juergens H and Craft A:
Safety assessment of intensive induction with vincristine,
ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of
Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr
Blood Cancer. 47:22–29. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leavey PJ, Mascarenhas L, Marina N, Chen
Z, Krailo M, Miser J, Brown K, Tarbell N, Bernstein ML, Granowetter
L, et al: Prognostic factors for patients with Ewing sarcoma (EWS)
at first recurrence following multi-modality therapy: A report from
the Children's oncology group. Pediatr Blood Cancer. 51:334–338.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stahl M, Ranft A, Paulussen M, Bölling T,
Vieth V, Bielack S, Görtitz I, Braun-Munzinger G, Hardes J, Jürgens
H and Dirksen U: Risk of recurrence and survival after relapse in
patients with Ewing sarcoma. Pediatr Blood Cancer. 57:549–553.
2001. View Article : Google Scholar
|
|
7
|
Moher D, Shamseer L, Clarke M, Ghersi D,
Liberati A, Petticrew M, Shekelle P and Stewart LA; PRISMA-P Group,
: Preferred reporting items for systematic review and meta-analysis
protocols (PRISMA-P) 2015 statement. Syst Rev. 4:12015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chugh R, Wathen JK, Maki RG, Benjamin RS,
Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML,
et al: Phase II multicenter trial of imatinib in 10 histologic
subtypes of sarcoma using a bayesian hierarchical statistical
model. J Clin Oncol. 27:3148–3153. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dumont SN, Trent JC, Patel S, Araujo DM,
Dumont AG and Benjamin RS: A phase II study of low-dose protracted
irinotecan in patients with advanced sarcomas. J Clin Oncol.
29:100642011. View Article : Google Scholar
|
|
10
|
Bisogno G, Riccardi R, Ruggiero A,
Arcamone G, Prete A, Surico G, Provenzi M, Bertolini P, Paolucci P
and Carli M: Phase II study of a protracted irinotecan schedule in
children with refractory or recurrent soft tissue sarcoma. Cancer.
106:703–707. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van Winkle P, Angiolillo A, Krailo M,
Cheung YK, Anderson B, Davenport V, Reaman G and Cairo MS:
Ifosfamide, carboplatin, and etoposide (ICE) reinduction
chemotherapy in a large cohort of children and adolescents with
recurrent/refractory sarcoma: The Children's cancer group (CCG)
experience. Pediatr Blood Cancer. 44:338–347. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Owens C, Laurence V, Benboubker L,
Defachelles AS, Cupissol D, Rubie H, Brisse H, Rey A, Ollivier L,
Couanet D, et al: Phase II study of cisplatin and oral VP16 in
patients with refractory or relapsed Ewing sarcoma. Cancer
Chemother Pharmacol. 71:399–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dileo P, Grosso F, Casanova M, Jimeno J,
Marsoni S, Podda RS, Ferrari S, Bertulli R and Casali PG:
Trabectedin (T) in metastatic Ewing's family tumors (EFT) patients
(pts) progressing after standard chemotherapy. J Clin Oncol.
25:100402007.
|
|
14
|
Zwerdling T, Krailo M, Monteleone P, Byrd
R, Sato J, Dunaway R, Seibel N, Chen Z, Strain J and Reaman G;
Children's Oncology Group, : Phase II investigation of docetaxel in
pediatric patients with recurrent solid tumors: A report from the
Children's oncology group. Cancer. 106:1821–1828. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Attia S, Bolejack V, Ganjoo KN, George S,
Agulnik M, Rushing DA, Loggers ET, Livingston MB, Wrig JA, Chawla
SP, et al: A phase II trial of regorafenib (REGO) in patients (pts)
with advanced Ewing sarcoma and related tumors (EWS) of soft tissue
and bone: SARC024 trial results. J Clin Oncol. 35:110052017.
View Article : Google Scholar
|
|
16
|
Naing A, LoRusso P, Fu S, Hong DS,
Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA and Kurzrock
R: Insulin growth factor-receptor (IGF-1R) antibody cixutumumab
combined with the mTOR inhibitor temsirolimus in patients with
refractory Ewing's sarcoma family tumors. Clin Cancer Res.
18:2625–2631. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baruchel S, Pappo A, Krailo M, Baker KS,
Wu B, Villaluna D, Lee-Scott M, Adamson PC and Blaney SM: A phase 2
trial of trabectedin in children with recurrent rhabdomyosarcoma,
Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A
report from the Children's oncology group. Eur J Cancer.
48:579–585. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bomgaars LR, Bernstein M, Krailo M, Kadota
R, Das S, Chen Z, Adamson PC and Blaney SM: Phase II trial of
irinotecan in children with refractory solid tumors: A Children's
oncology group study. J Clin Oncol. 25:4622–4627. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schwartz GK, Tap WD, Qin LX, Livingston
MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR,
Okuno SH, et al: Cixutumumab and temsirolimus for patients with
bone and soft-tissue sarcoma: A multicentre, open-label, phase 2
trial. Lancet Oncol. 14:371–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wagner LM, Fouladi M, Ahmed A, Krailo MD,
Weigel B, DuBois SG, Doyle LA, Chen H and Blaney SM: Phase II study
of cixutumumab in combination with temsirolimus in pediatric
patients and young adults with recurrent or refractory sarcoma: A
report from the Children's oncology group. Pediatr Blood Cancer.
62:440–444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Minard-Colin V, Ichante JL, Nguyen L, Paci
A, Orbach D, Bergeron C, Defachelles AS, André N, Corradini N,
Schmitt C, et al: Phase II study of vinorelbine and continuous low
doses cyclophosphamide in children and young adults with a relapsed
or refractory malignant solid tumour: good tolerance profile and
efficacy in rhabdomyosarcoma-a report from the Société Française
des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE). Eur
J Cancer. 48:2409–2416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jones RL, Ferrari S, Blay JY, Navid F,
Lardelli P, Alfaro V, Siguero M, Soman N and Chawla SP: A Phase II
multicenter, open-label, clinical and pharmokinetic trial of
PM00104 in patients with advanced Ewing family of tumors. Invest
New Drugs. 32:171–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Duffaud F and Therasse P: New guidelines
to evaluate the response to treatment in solid tumors. Bull Cancer.
87:881–886. 2000.(In French). PubMed/NCBI
|
|
25
|
Park JO, Lee SI, Song SY, Kim K, Kim WS,
Jung CW, Park YS, Im YH, Kang WK, Lee MH, et al: Measuring response
in solid tumors: Comparison of RECIST and WHO response criteria.
Jpn J Clin Oncol. 33:533–537. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miller AB, Hoogstraten B, Staquet M and
Winkler A: Reporting results of cancer treatment. Cancer.
47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choi H, Charnsangavej C, Faria SC,
Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and
Benjamin RS: Correlation of computed tomography and positron
emission tomography in patients with metastatic gastrointestinal
stromal tumor treated at a single institution with imatinib
mesylate: Proposal of new computed tomography response criteria. J
Clin Oncol. 25:1753–1759. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Palmerini E, Jones RL, Setola E, Picci P,
Marchesi E, Luksch R, Grignani G, Cesari M, Longhi A, Abate ME, et
al: Irinotecan and temozolomide in recurrent Ewing sarcoma: an
analysis in 51 adult and pediatric patients. Acta Oncol.
57:958–964. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Raciborska A, Bilska K, Drabko K, Chaber
R, Pogorzala M, Wyrobek E, Polczyńska K, Rogowska E,
Rodriguez-Galindo C and Wozniak W: Vincristine, irinotecan, and
temozolomide in patients with relapsed and refractory Ewing
sarcoma. Pediatr Blood Cancer. 60:1621–1625. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kurucu N, Sari N and Ilhan IE: Irinotecan
and temozolamide treatment for relapsed Ewing sarcoma: A
single-center experience and review of the literature. Pediatr
Hematol Oncol. 32:50–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mir O, Brodowicz T, Italiano A, Wallet J,
Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas
S, et al: Safety and efficacy of regorafenib in patients with
advanced soft tissue sarcoma (REGOSARC): A randomised,
double-blind, placebo-controlled, phase 2 trial. Lancet Oncol.
17:1732–1742. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
van der Graaf WT, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppu Y, et al: Pazopanib for metastatic soft-tissue sarcoma
(PALETTE): A randomised, double-blind, placebo-controlled phase 3
trial. Lancet. 379:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie L, Guo W, Wang Y, Yan T, Ji T and Xu
J: Apatinib for advanced sarcoma: Results from multiple
institutions' off-label use in China. BMC Cancer. 18:3962018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alcindor T: Response of refractory Ewing
sarcoma to pazopanib. Acta Oncol. 54:1063–1064. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamamoto Y, Nozawa M, Shimizu N, Minami T,
Yoshimura K and Uemura H: Pazopanib for recurrent extraosseous
Ewing's sarcoma of the retroperitoneum. Int J Urol. 21:1183–1184.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Attia S, Okuno SH, Robinson SI, Webber NP,
Indelicato DJ, Jones RL, Bagaria SP, Jones RL, Sherman C, Kozak KR,
et al: Clinical activity of pazopanib in metastatic extraosseous
Ewing sarcoma. Rare Tumors. 7:59922015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mori Y, Kinoshita S, Kanamori T, Kataoka
H, Joh T, Iida S, Takemoto M, Kondo M, Kuroda J and Komatsu H: The
successful treatment of metastatic extraosseous Ewing sarcoma with
pazopanib. Intern Med. 57:2753–2757. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Italiano A, Penel N, Toulmonde M, Bompas
E, Piperno-Neumann S, Pulido M, Entz-Werle N, Le Cesne A, Chevreau
CM, Duffaud F, et al: LBA67-Cabozantinib in Patients With Advanced
Osteosarcomas and Ewing sarcomas: A French Sarcoma Group (FSG)/US
National Cancer Institute phase II collaborative study. From ESMO
2018 congress, Proffered Paper session. https://cslide.ctimeetingtech.com/library/esmo/browse/search/2AuE#2Ea3302NBOctober
19–2018
|
|
39
|
Liu K, Ren T, Huang Y, Sun K, Bao X, Wang
S, Zheng B and Guo W: Apatinib promotes autophagy and apoptosis
through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death
Dis. 8:e30152017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Canu B, Fioravanti A, Orlandi P, Di
Desidero T, Ali G, Fontanini G, Di Paolo A, Del Tacca M, Danesi R
and Bocci G: Irinotecan synergistically enhances the
antiproliferative and proapoptotic effects of axitinib in vitro and
improves its anticancer activity in vivo. Neoplasia. 13:217–229.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hashimoto K, Man S, Xu P, Cruz-Munoz W,
Tang T, Kumar R and Kerbel RS: Potent preclinical impact of
metronomic low-dose oral topotecan combined with the antiangiogenic
drug pazopanib for the treatment of ovarian cancer. Mol Cancer
Ther. 9:996–1006. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mego M, Chovanec J, Vochyanova-Andrezalova
I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B,
Beniak J, Medvecova L, et al: Prevention of irinotecan induced
diarrhea by probiotics: A randomized double blind, placebo
controlled pilot study. Complement Ther Med. 23:356–362. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kimura K, Yamano T, Igeta M, Imada A,
Jihyung S, Babaya A, Hamanaka M, Kobayashi M, Tsukamoto K, Noda M,
et al: UGT1A1 polymorphisms in rectal cancer associated with the
efficacy and toxicity of preoperative chemoradiotherapy using
irinotecan. Cancer Sci. 109:3934–3942. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
De Wit M, Boers-Doets CB, Saettini A,
Vermeersch K, de Juan CR, Ouwerkerk J, Raynard SS, Bazin A and
Cremolini C: Prevention and management of adverse events related to
regorafenib. Support Care Cancer. 22:837–846. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Milling RV, Grimm D, Krüger M, Grosse J,
Kopp S, Bauer J, Infanger M and Wehland M: Pazopanib, cabozantinib,
and vandetanib in the treatment of progressive medullary thyroid
cancer with a special focus on the adverse effects on hypertension.
Int J Mol Sci. 19(pii): E32582018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sharma S, Abhyankar V, Burgess RE, Infante
J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y and Robles
RL: A phase I study of axitinib (AG-013736) in combination with
bevacizumab plus chemotherapy or chemotherapy alone in patients
with metastatic colorectal cancer and other solid tumors. Ann
Oncol. 21:297–304. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bennouna J, Deslandres M, Senellart H, de
Labareyre C, Ruiz-Soto R, Wixon C, Botbyl J, Suttle AB and Delord
JP: A phase I open-label study of the safety, tolerability, and
pharmacokinetics of pazopanib in combination with irinotecan and
cetuximab for relapsed or refractory metastatic colorectal cancer.
Invest New Drugs. 33:138–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Garofalo C, Mancarella C, Grilli A, Manara
MC, Astolfi A, Marino MT, Conte A, Sigismund S, Carè A, Belfiore A,
et al: Identification of common and distinctive mechanisms of
resistance to different anti-IGF-IR agents in Ewing's sarcoma. Mol
Endocrinol. 26:1603–1616. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Manara MC, Landuzzi L, Nanni P, Nicoletti
G, Zambelli D, Lollini PL, Nanni C, Hofmann F, Garcia-Echeverria C,
Picci P and Scotlandi K: Preclinical in vivo study of new
insulin-like growth factor-I receptor-specific inhibitor in Ewing's
sarcoma. Clin Cancer Res. 13:1322–1330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chan TA, Yarchoan M, Jaffee E, Swanton C,
Quezada SA, Stenzinger A and Peters S: Development of tumor
mutation burden as an immunotherapy biomarker: Utility for the
oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tong M, Wang J, He W, Wang Y, Pan H, Li D
and Zhang H: Predictive biomarkers for tumor immune checkpoint
blockade. Cancer Manag Res. 10:4501–4507. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Campbell BB, Light N, Fabrizio D, Zatzman
M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel
KP, et al: comprehensive analysis of hypermutation in human cancer.
Cell. 171:1042–1056 e10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Crompton BD, Stewart C, Taylor-Weiner A,
Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA,
Mehta SS, et al: The genomic landscape of pediatric Ewing sarcoma.
Cancer Discov. 4:1326–1341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sand LG, Szuhai K and Hogendoorn PC:
Sequencing overview of ewing sarcoma: A journey across genomic,
epigenomic and transcriptomic landscapes. Int J Mol Sci.
16:16176–16215. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Aras M, Erdil TY, Dane F, Gungor S, Ones
T, Dede F, Inanir S and Turoglu HT: Comparison of WHO, RECIST 1.1,
EORTC, and PERCIST criteria in the evaluation of treatment response
in malignant solid tumors. Nucl Med Commun. 37:9–15.
2016.PubMed/NCBI
|
|
56
|
Schuetze SM, Wathen JK, Lucas DR, Choy E,
Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM,
et al: SARC009: Phase 2 study of dasatinib in patients with
previously treated, high-grade, advanced sarcoma. Cancer.
122:868–874. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ronot M, Bouattour M, Wassermann J, Bruno
O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond
E and Faivre S: Alternative Response Criteria [Choi, European
association for the study of the liver, and modified Response
Evaluation Criteria in Solid Tumors (RECIST)] versus RECIST 1.1 in
patients with advanced hepatocellular carcinoma treated with
sorafenib. Oncologist. 19:394–402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Beaty O III, Berg S, Blaney S,
Malogolowkin M, Krailo M, Knight R, Schaiquevich P, Stewart C, Chen
Z, Nelson M, et al: A phase II trial and pharmacokinetic study of
oxaliplatin in children with refractory solid tumors: A Children's
oncology group study. Pediatr Blood Cancer. 55:440–445. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Subbiah V, Sankhala KK, Ratan R, Garcia
ES, Boni V, Gill T, Villalobos VM, Chawla SP, Lardelli P, Siguero
M, et al: Efficacy and safety of lurbinectedin (PM1183) in Ewing
sarcoma: Final results from a phase 2 study. J Clin Oncol.
36:115192018. View Article : Google Scholar
|
|
60
|
Michelagnoli M, Whelan J and Forsyth S;
OTIS Trial Management Group, Site Investigators, : A phase II study
to determine the efficacy and safety of oral treosulfan in patients
with advanced pre-treated Ewing sarcoma ISRCTN11631773. Pediatr
Blood Cancer. 62:158–159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hawkins DS, Bradfield S, Whitlock JA,
Krailo M, Franklin J, Blaney SM, Adamson PC and Reaman G: Topotecan
by 21-day continuous infusion in children with relapsed or
refractory solid tumors: A Children's oncology group study. Pediatr
Blood Cancer. 47:790–794. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Fox E, Patel S, Wathen JK, Schuetze S,
Chawla S, Harmon D, Reinke D, Chugh R, Benjamin RS and Helman LJ:
Phase II study of sequential gemcitabine followed by docetaxel for
recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally
recurrent chondrosarcoma: Results of Sarcoma Alliance for Research
Through Collaboration Study 003. Oncologist. 17:3212012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Jacobs S, Fox E, Krailo M, Hartley G,
Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, et
al: Phase II trial of ixabepilone administered daily for five days
in children and young adults with refractory solid tumors: A report
from the Children's oncology group. Clin Cancer Res. 16:750–754.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
DuBois SG, Krailo MD, Lessnick SL, Smith
R, Chen Z, Marina N, Grier HE and Stegmaier K; Children's Oncology
Group, : Phase II study of intermediate-dose cytarabine in patients
with relapsed or refractory Ewing sarcoma: A report from the
Children's oncology group. Pediatr Blood Cancer. 52:324–327. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Warwick AB, Malempati S, Krailo M, Melemed
A, Gorlick R, Ames MM, Safgren SL, Adamson PC and Blaney SM: Phase
2 trial of pemetrexed in children and adolescents with refractory
solid tumors: A Children's oncology group study. Pediatr Blood
Cancer. 60:237–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Grohar PJ, Glod J, Peer CJ, Sissung TM,
Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ and Widemann
BC: A phase I/II trial and pharmacokinetic study of mithramycin in
children and adults with refractory Ewing sarcoma and EWS-FLI1
fusion transcript. Cancer Chemother Pharmacol. 80:645–652. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chao J, Budd GT, Chu P, Frankel P, Garcia
D, Junqueira M, Loera S, Somlo G, Sato J and Chow WA: Phase II
clinical trial of imatinib mesylate in therapy of KIT and/or
PDGFRalpha-expressing Ewing sarcoma family of tumors and
desmoplastic small round cell tumors. Anticancer Res. 30:547–552.
2010.PubMed/NCBI
|
|
68
|
Bond M, Bernstein ML, Pappo A, Schultz KR,
Krailo M, Blaney SM and Adamson PC: A phase II study of imatinib
mesylate in children with refractory or relapsed solid tumors: A
Children's oncology group study. Pediatr Blood Cancer. 50:254–258.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Choy E, Butrynski JE, Harmon DC, Morgan
JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH,
et al: Phase II study of olaparib in patients with refractory Ewing
sarcoma following failure of standard chemotherapy. BMC Cancer.
14:8132014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
University of Oxford: Phase II trial of
Linsitinib (anti-IGFR/IR) in patients with relapsed and/or
refractory Ewing Sarcoma. 2015.https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000616-28/resultsNovember
2–2018
|
|
71
|
Children's Oncology Group, : Alisertib in
treating young patients with recurrent or refractory solid tumors
or leukemia. 2017.https://clinicaltrials.gov/ct2/show/results/NCT01154816November
2–2018
|
|
72
|
Juergens H, Daw NC, Geoerger B, Ferrari S,
Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, et al:
Preliminary efficacy of the anti-insulin-like growth factor type 1
receptor antibody figitumumab in patients with refractory Ewing
sarcoma. J Clin Oncol. 29:4534–4540. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Tap WD, Demetri G, Barnette P, Desai J,
Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H, McCaffery I, et
al: Phase II study of ganitumab, a fully human anti-type-1
insulin-like growth factor receptor antibody, in patients with
metastatic Ewing family tumors or desmoplastic small round cell
tumors. J Clin Oncol. 30:1849–1856. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Pappo AS, Patel SR, Crowley J, Reinke DK,
Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, et
al: R1507, a monoclonal antibody to the insulin-like growth factor
1 receptor, in patients with recurrent or refractory Ewing sarcoma
family of tumors: Results of a phase II sarcoma alliance for
research through collaboration study. J Clin Oncol. 29:4541–4547.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Anderson PM, Bielack SS, Gorlick RG,
Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E,
Pápai Z, et al: A phase II study of clinical activity of SCH 717454
(robatumumab) in patients with relapsed osteosarcoma and Ewing
sarcoma. Pediatr Blood Cancer. 63:1761–1770. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Malempati S, Weigel B, Ingle AM, Ahern CH,
Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, et
al: Phase I/II trial and pharmacokinetic study of cixutumumab in
pediatric patients with refractory solid tumors and Ewing sarcoma:
A report from the Children's oncology group. J Clin Oncol.
30:256–262. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Schöffski P, Adkins D, Blay JY, Gil T,
Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H,
Willey R and Grebennik DO: An open-label, phase 2 study evaluating
the efficacy and safety of the anti-IGF-1R antibody cixutumumab in
patients with previously treated advanced or metastatic soft-tissue
sarcoma or Ewing family of tumours. Eur J Cancer. 49:3219–3228.
2013. View Article : Google Scholar : PubMed/NCBI
|
